E-ISSN 2602-3164
EJMI. 2024; 8(4): 269-273 | DOI: 10.14744/ejmi.2024.68903

Soft Tissue Sarcomas: Insights from a Single-Center Retrospective Study

Yakup Duzkopru1, Guner Akguner2
1Department of Medical Oncology, Aksaray Training and Research Hospital, Aksaray, Türkiye, 2Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Türkiye

Objectives: Soft tissue sarcomas (STS) are a heterogeneous group of rare malignancies with diverse histopathological subtypes. This study aimed to evaluate the clinical, demographic, and pathological characteristics of STS patients and their treatment outcomes. Methods: A retrospective analysis was conducted on 41 STS patients diagnosed between January 2016 and January 2021. Patient data, including tumor subtype, location, metastasis, and treatment, were analyzed using descriptive statistics and survival analysis. Results: The median age was 64 years, with 63.4% male patients. Malignant mesenchymal tumors and Kaposi sarcomas were the most common subtypes (22% each), and extremities and trunk were the most frequent tumor sites (58.5%). Lung metastases were observed in 36.6% of patients. First-line treatment predominantly involved the IMA protocol, while pazopanib was the most used second-line therapy. Median overall survival was 16 months. Conclusion: Leiomyosarcomas were the most prevalent subtype, with the extremities and trunk being the primary tumor sites and the lungs the predominant metastatic location. Anthracycline-based regimens and gemcitabinedocetaxel remain the cornerstone treatments for metastatic STS. Larger studies are needed to confirm these findings. Keywords: Soft tissue sarcoma, leiomyosarcoma, chemotherapy, pazopanib, targeted therapies


Cite This Article

Duzkopru Y, Akguner G. Soft Tissue Sarcomas: Insights from a Single-Center Retrospective Study. EJMI. 2024; 8(4): 269-273

Corresponding Author: Yakup Duzkopru

Full Text PDF PDF Download
EJMI & EJMI